Group 1 - The Hong Kong stock market experienced a collective pullback after four consecutive days of gains, with the Hong Kong Stock Connect Innovative Drug ETF (159570) dropping over 2.5% and quickly surpassing a trading volume of 1.3 billion HKD [1][3] - Rongchang Biopharmaceutical announced a licensing agreement for its proprietary drug Taitasip to Vor Bio, which includes a cash payment of 125 million USD and potential milestone payments totaling up to 4.105 billion USD, leading to a significant drop in Rongchang's stock price [3][4] - Other stocks within the Hong Kong Stock Connect Innovative Drug ETF also saw declines, including Innovent Biologics down nearly 4% and CanSino Biologics down over 3% [3] Group 2 - The current innovative drug market is characterized by a revaluation of assets, driven by the recognition of the commercial viability of leading companies, which is expected to continue as the market acknowledges the long-term value of R&D investments [5][6] - The market's focus has shifted towards data asset pricing rather than business development (BD) pricing, indicating that high-quality R&D data will attract reasonable market valuations regardless of short-term BD fluctuations [6] - Recent regulatory support from the drug administration aims to shorten clinical trial approval times and promote international collaboration in drug development, highlighting the strategic importance of innovative drugs for national security and economic growth [7] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (159570) has a strong focus on the innovative drug sector, with nearly 72% of its top ten holdings in leading companies, indicating a concentrated investment strategy [8] - The ETF has shown significant performance, with a nearly 99% increase over the past year, outperforming other medical indices [8] - The underlying assets of the ETF are traded on the Hong Kong stock market, allowing for T+0 trading, which enhances liquidity and investment flexibility [8]

金融界6月25日消息，上证指数低开高走，中证沪深港生物科技主题指数 (沪深港生物科技主题， 932245)报1352.64点。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。当特殊情况下将对指数进行临时调整。当样本退市时，将其从指数 样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。当沪股通、深 股通和港股通证券范围发生变动导致样本不再满足互联互通资格时，指数将相应调整。 本文源自：金融界 作者：行情君 从指数持仓来看，中证沪深港生物科技主题指数十大权重分别为：恒瑞医药（12.02%）、百济神州 （10.82%）、药明康德（8.63%）、迈瑞医疗（7.04%）、信达生物（6.24%）、药明生物（4.88%）、 康方生物（3.31%）、石药集团（3.04%）、中国生物制药（2.78%）、三生制药（2.05%）。 从中证沪深港生物科技主题指数持仓的市场板块来看，香港证券交易所占比45.80%、上海证券交易所 占比33 ...

Core Viewpoint - The healthcare sector is experiencing positive momentum driven by favorable policy signals and strong performance of the Hang Seng Healthcare Index and related ETFs [2][3]. Group 1: Market Performance - As of June 25, 2025, the Hang Seng Healthcare Index (HSHCI) rose by 1.37%, with notable increases in stocks such as Cloudmed (01952) up 4.52% and JD Health (06618) up 3.16% [1]. - The Hang Seng Healthcare ETF (513060) also saw a rise of 1.58%, marking its fourth consecutive increase, with a latest price of 0.58 yuan [1]. - The ETF recorded a turnover of 3.26 billion yuan, with a turnover rate of 3.98% during the trading session [1]. Group 2: Policy and Industry Insights - Recent policies from the National Medical Products Administration (NMPA) aim to streamline clinical trial approval processes, potentially reducing the time and costs associated with drug development [2]. - The China Drug Evaluation (CDE) reported a steady increase in clinical trials in oncology and autoimmune fields, indicating a growing demand for innovative drug companies and the CXO industry [2]. - The China Securities Regulatory Commission (CSRC) has introduced new listing standards for the ChiNext board, enhancing financing opportunities for unprofitable biotech companies [2]. Group 3: ETF Performance Metrics - The Hang Seng Healthcare ETF has seen a net value increase of 17.35% over the past two years, with a maximum monthly return of 28.34% since inception [3]. - The ETF's Sharpe ratio for the past year is reported at 1.66, indicating strong risk-adjusted returns [3]. - The ETF has the lowest drawdown among comparable funds, with a relative drawdown of 0.45% year-to-date [4]. Group 4: Valuation and Holdings - The Hang Seng Healthcare Index's latest price-to-earnings ratio (PE-TTM) stands at 27.44, which is below the historical average, suggesting a potentially undervalued market [4]. - The top ten weighted stocks in the Hang Seng Healthcare Index account for 58.34% of the index, with notable companies including Innovent Biologics (01801) and BeiGene (06160) [4].

Group 1 - The core viewpoint of the article highlights the significant performance of the CESHKB index, which has seen substantial increases over various time frames, indicating a strong market trend in the biotechnology sector in Hong Kong [1][2]. - The CESHKB index rose by 3.66% to 7559.76 points, with a trading volume of 12.113 billion [1]. - Over the past month, the CESHKB index has increased by 15.96%, by 28.51% over the last three months, and has risen 62.76% year-to-date [1]. Group 2 - The CESHKB index is compiled by China Securities Index Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1]. - The index is based on a reference date of December 12, 2014, with a base point of 2000.0 [1]. - The top ten holdings of the CESHKB index include companies such as CanSino Biologics (10.79%), Innovent Biologics (10.03%), and BeiGene (9.56%) [1]. Group 3 - The market composition of the CESHKB index is entirely based on the Hong Kong Stock Exchange [2]. - In terms of industry distribution, biopharmaceuticals account for 56.98%, pharmaceutical and biotechnology services for 24.70%, chemical drugs for 16.03%, and medical devices for 2.29% [2].

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong Stock Connect Innovative Drug Index, which rose by 3.4% to 955.16 points, with a trading volume of 16.275 billion yuan [1] - The index has shown significant growth, increasing by 15.52% over the past month, 30.95% over the past three months, and 58.83% year-to-date [1] - The index comprises 50 listed companies involved in innovative drug research and development, reflecting the overall performance of innovative drug companies within the Hong Kong Stock Connect [1] Group 2 - The top ten weighted companies in the index include Innovent Biologics (10.14%), BeiGene (9.67%), WuXi Biologics (9.53%), and others, indicating a concentration in leading firms within the innovative drug sector [1] - The index is exclusively composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation from this market [1] - The industry composition of the index shows that drug formulations account for 42.00%, other biopharmaceuticals for 38.03%, pharmaceutical and biotechnology services for 19.53%, and vaccines for 0.44% [2] Group 3 - The index undergoes adjustments every six months, specifically on the second Friday of June and December, with weight factors adjusted accordingly [2] - In special circumstances, the index may be adjusted temporarily, such as when a sample company is delisted or undergoes mergers or acquisitions [2] - Changes in the Hong Kong Stock Connect eligibility may also lead to adjustments in the index samples [2]

Core Points - The China Securities Index for Hong Kong Stock Connect Medical Theme Index has shown a significant increase, with a rise of 3.01% to 896.72 points on June 24, with a trading volume of 13.184 billion [1] - Over the past month, the index has increased by 7.54%, by 6.79% over the last three months, and has risen by 30.22% year-to-date [1] Index Composition - The index consists of 50 listed companies involved in medical devices, medical business and services, pharmaceuticals, and biotechnology services, reflecting the overall performance of the medical sector within the Hong Kong Stock Connect [1] - The index was established on December 31, 2018, with a base point of 1000.0 [1] Top Holdings - The top ten weighted stocks in the index are: WuXi Biologics (14.49%), JD Health (10.5%), WuXi AppTec (5.95%), Alibaba Health (5.78%), Sinopharm (5.12%), Genscript Biotech (4.67%), Weigao Group (3.39%), MicroPort Scientific (2.5%), China Biologic Products (2.25%), and CanSino Biologics (2.24%) [1] Sector Allocation - The index's holdings are entirely from the Hong Kong Stock Exchange, with sector allocations as follows: Medical Business and Services (35.09%), Pharmaceutical and Biotechnology Services (31.59%), Medical Devices (12.87%), Chemical Drugs (12.53%), and Biological Drugs (7.91%) [2] Index Adjustment - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2]

金融界6月24日消息，上证指数低开高走，中证港股通生物科技主题指数 (港股通生物科技，932253)报 1513.97点。 数据统计显示，中证港股通生物科技主题指数近一个月上涨15.00%，近三个月上涨27.95%，年至今上 涨60.32%。 据了解，中证港股通生物科技主题指数从港股通范围内选取50只业务涉及生物药品、制药与生物科技服 务等领域的上市公司证券作为指数样本，以反映港股通范围内生物科技主题上市公司证券的整体表现。 该指数以2018年12月28日为基日，以1000.0点为基点。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。每次调整的样本比例一般不超过20%。权重因子随样本定期调整而调整，调整时间与指数样本 定期调整实施时间相同。在下一个定期调整日前，权重因子一般固定不变。特殊情况下将对指数进行临 时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照 计算与维护细则处理。当港股通范围发生变动导致样本不再满足互联互通资格时，指数将相应调整。 本文源自：金融界 作者：行情君 从指数持仓来看，中证港股通生物科技主 ...

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, indicating strong investor interest in the innovative drug sector [1]. Group 1: Fund Performance - As of June 24, the Hong Kong Innovative Drug ETF (159567) closed with a gain of 2.25% and a trading volume of 2.373 billion yuan [1]. - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1]. - The latest share count reached 1.478 billion, with a total fund size of 2.217 billion yuan as of June 23, reflecting a 273.92% increase in shares and a 486.71% increase in size since December 31, 2024 [1]. Group 2: Liquidity and Trading Activity - Over the last 20 trading days, the ETF recorded a cumulative trading amount of 38.434 billion yuan, averaging 1.922 billion yuan per day [1]. - Year-to-date, the ETF has seen a total trading amount of 79.325 billion yuan over 113 trading days, averaging 0.702 billion yuan per day [1]. Group 3: Fund Management - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 49.94% during the management period [1]. Group 4: Top Holdings - The ETF's top holdings include WuXi Biologics (11.47%), BeiGene (10.87%), and Innovent Biologics (9.60%), among others, with significant market values attributed to each [2].

Group 1 - The Hong Kong stock market is experiencing a collective rise, with the Hong Kong Stock Connect Innovative Drug ETF (159570) surging over 2% and achieving a trading volume exceeding 1.4 billion yuan [1] - As of 10:25, most constituent stocks of the Hong Kong Stock Connect Innovative Drug ETF (159570) are performing well, with Rongchang Bio rising over 6% and several other companies like CSPC Pharmaceutical, WuXi Biologics, and BeiGene increasing by over 2% [3] - Recent policies have provided support for innovative drugs and medical devices, including discussions on the adjustment of the national medical insurance drug list and optimization of clinical trial approvals [4] Group 2 - The pharmaceutical and biotechnology sector experienced significant declines last week, but the innovative drug sector has shown strong performance year-to-date, indicating a potential for medium to long-term investment opportunities despite short-term adjustments [5] - The China Securities Regulatory Commission has proposed measures to expedite the review and approval process for innovative drug clinical trials, aiming to encourage the development and market entry of innovative drugs [5] - The 2025 mid-term investment strategy emphasizes the importance of both domestic stability and international expansion, highlighting China's competitive advantages in population, manufacturing, and innovation capabilities [6][8] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (159570) has a strong focus on the innovative drug industry, with nearly 72% of its top ten holdings in leading companies [8] - The ETF is characterized by a high concentration in innovative drugs, with an 85% weight in this category, and is currently undervalued compared to historical price-to-sales ratios [8] - The ETF allows for T+0 trading and is positioned as a medium-risk investment suitable for balanced investors [8]

把握创新药行情投资机遇，港股创新药ETF（513120）凭借三大优势成为资金布局首选：一是跟踪的中证香港创新药指数，其申万二级创新药企权重超过 91%，精准覆盖药明生物、信达生物等龙头企业；二是港股创新药ETF最新规模达125亿元，月内日均成交额超75亿元，规模、流动性均同类居首；三是 支持T+0交易，操作灵活。场外投资者可通过其联接基金（A类019670，C类019671）便捷布局。 展望后市，中泰证券指出，从基本面来看，创新药仍是当前医药板块中产业趋势最为明确且具备未来成长空间的子行业，我们认为全年维度创新药作为医 药板块的投资主线不会变化，短暂调整后板块有望在分化中持续上涨，在调整中建议坚守相对主流的优质创新药标的，以及将有BD或是数据催化的公 司。 EASY ETF 这样投资更简单! 发中证香港创新药ETF 513120 寫 港股创新药ETF 联接A: 019670 联接C:019671 6月以来，港股创新药板块持续成为市场焦点，交投持续活跃。以全市场规模最大的港股创新药ETF（513120）为例，截至6月23日，该产品连续10个交易 日持续获资金净买入，最新规模超125亿元，月内日均成交额超75亿元 ...